Clinical trial NCT05423275: Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Official title: Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Major Depressive Disorder, Recurrent, in Remission
Keywords: antidepressants
discontinuation
relapse prevention
light therapy
negative ions
depression
Lead sponsor: University of British Columbia
Sponsor class: OTHER
Collaborators: name: University of Toronto
name: Université de Montréal
name: Canadian Institutes of Health Research (CIHR)
name: McMaster University
name: Ontario Brain Institute
name: Centre for Addiction and Mental Health
First posted: 2022-06-21
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, two-group, parallel, relapse prevention design
Primary purpose: TREATMENT

Brief summary: Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to prevent relapse but many people stop antidepressants too soon relapse into another depressive episode. We will test non-medication treatments, negative ion therapy and light therapy, to see they can substitute for antidepressants to prevent relapse. This is a "feasibility" study to see if participants use study treatments properly, before doing a larger, definitive trial. In this 28-week study, 100 participants with MDD who are in remission with antidepressants will be treated with light therapy or negative ion therapy (with half of devices active and half inactive) while slowly discontinuing the antidepressant, and monitored for relapse.

Detailed description: The purpose of this study is to evaluate the feasibility of a multicentre, randomized, trial of light therapy and negative ion therapy as substitutes for antidepressants for maintenance treatment for patients with recurrent major depressive disorder (MDD).

The study design for this feasibility study mirrors the full LIMIT-D protocol: a 28-week, double-blind (participant and outcome rater) relapse prevention study with 100 participants randomized 1:1 to one of two study treatments, light therapy or negative ion therapy, and assessed for relapse over 28 weeks. Half the study devices are modified to be inactive. After 2 weeks of study treatment, the participant's antidepressant will be tapered and discontinued between Week 2 and Week 8.

Participants are assessed for relapse at each scheduled study visit (every 2 weeks during antidepressant taper until week 8, then every 4 weeks until end of study treatment at Week 28) by blind outcome raters. In addition, they complete an online Personal Health Questionnaire (PHQ-9) self-rated depression symptom scale bi-weekly; if total score is 10 or higher OR the suicide item score is 2 or higher, participants are booked for a relapse-assessment visit and relapse-verification study visit at least 1 week apart. Relapse will be defined as any of the following:

1. MADRS total score 20 or higher for at least 2 consecutive weeks and Diagnostic and Statistical Manual (DSM-5) criteria for major depressive episode at the Relapse-Verification visit.
2. Hospitalization for worsening of depression.
3. Suicidal ideation with intent or plan, or suicidal behaviour.
4. Any change in treatment for depression (e.g., starting an antidepressant).

At each visit, clinician-rated and self-rated symptom, side effect, and functioning measures are completed. The primary feasibility outcome is recruitment rate; secondary feasibility outcomes include adherence to study treatment, successful discontinuation of antidepressants rate, and all-cause dropout rate. Secondary clinical outcomes include relapse rate, time to relapse, adverse events, and safety profiles.

Participants will wear an actigraph at home during the 28-week study treatment period to assess sleep, light and activity/circadian rhythms. There is a final observational visit by Zoom videoconference at Week 52.

Eligibility criteria: Inclusion Criteria:

* Diagnostic and Statistical Manual (DSM-5) criteria for MDD, as determined by the Structured Clinical Interview for DSM-5 (SCID).
* Taking a first-line antidepressant at approved doses (Table 1), with dose unchanged in the past month.
* Participant desire to discontinue antidepressant treatment because of adverse effects or other reasons;
* In remission as defined by score ≤10 on the clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) at both the screening visit and baseline visit, at least 2 weeks apart.
* Willing and able to complete self-report and online assessments including sufficient fluency in English or French.

Exclusion Criteria:

* Any psychiatric diagnosis other than MDD that is considered the primary diagnosis, including Bipolar I or Bipolar-II (lifetime). Note that comorbid anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder) will not be excluded if the anxiety disorder is not the primary diagnosis.
* Diagnosis of MDD with seasonal pattern (i.e., seasonal affective disorder, SAD) or with psychotic features (lifetime).
* Significant personality disorder diagnosis \[e.g., antisocial\] by MINI and clinical assessment.
* High suicidal risk, defined by clinician judgment.
* History of alcohol or substance use disorder, with a severity of at least moderate or severe, within 6 months before screening.
* Significant neurological disorders, head trauma, or other unstable medical conditions.
* Regular use of psychotropic medication other than an antidepressant or benzodiazepines (e.g., antipsychotics, mood stabilizers); Note - Stimulant medications for Attention-Deficit Hyperactivity Disorder are allowed if dose is stable in past month.
* History of severe antidepressant discontinuation effects.
* Retinal disease or other eye condition (e.g., macular degeneration) precluding the use of bright light treatment.
* Use of photosensitizing medication (thioridazine, chloroquine, 8-methoxypsoralen) within 1 week of baseline visit.
* Initiated formal psychotherapy (e.g., cognitive-behavioural therapy) within 3 months of Visit 1, or who plan to initiate psychotherapy during the study.
* Continued use of any other evidence-based treatment for depression.

Primary outcomes:
measure: Recruitment rate
timeFrame: 36 months
Secondary outcomes:
measure: Adherence to study treatment
timeFrame: 28 weeks
measure: Rate of stopping antidepressants
timeFrame: 8 weeks
measure: All-cause dropout rate
timeFrame: 28 weeks
Other outcomes:
measure: Time to relapse
timeFrame: 28 weeks
measure: Relapse rate
timeFrame: 28 weeks
measure: Adverse events
timeFrame: 28 weeks
measure: Serious adverse events
timeFrame: 28 weeks
Locations:
city: Vancouver
country: Canada
facility: Djavad Mowafaghian Centre for Brain Health
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Raymond W Lam, MD
role: PRINCIPAL_INVESTIGATOR
References: